Drug Type Small molecule drug |
Synonyms 苏特替尼 |
Mechanism EGFR L861Q mutation antagonists, EGFR S768I mutation antagonists, EGFR-G719X inhibitors(EGFR-G719X inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationBreakthrough Therapy (CN) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Locally Advanced Lung Non-Small Cell Carcinoma | Phase 2 | US | 01 Sep 2022 | |
Locally Advanced Lung Non-Small Cell Carcinoma | Phase 2 | CN | 01 Sep 2022 | |
EGFR positive non-small cell lung cancer | Phase 2 | CN | 29 Nov 2021 | |
EGFR positive non-small cell lung cancer | Phase 2 | CN | 29 Nov 2021 | |
EGFR-mutated non-small Cell Lung Cancer | Phase 1 | CN | 01 Aug 2023 | |
EGFR-mutated non-small Cell Lung Cancer | Phase 1 | CN | 01 Aug 2023 | |
Advanced Malignant Solid Neoplasm | Phase 1 | CN | 06 Jan 2017 | |
Advanced Malignant Solid Neoplasm | Phase 1 | CN | 06 Jan 2017 |
CTR20190681 (ASCO2023) Manual | Phase 2 | EGFR-mutated non-small Cell Lung Cancer EGFR Mutation | 30 | adzbzniwyd(ctdquoqztt) = dzfufqwibw tqxqlojavl (fwurofllnb ) View more | Positive | 26 May 2023 | |
adzbzniwyd(ctdquoqztt) = qckqbqjbre tqxqlojavl (fwurofllnb ) View more |